1.Epididymosomes are involved in the acquisition of new sperm proteins during epididymal transit.
Robert SULLIVAN ; Gilles FRENETTE ; Julie GIROUARD
Asian Journal of Andrology 2007;9(4):483-491
During epididymal transit, spermatozoa acquire new proteins. Some of these newly acquired proteins behave as integral membrane proteins, including glycosylphosphatidylinositol (GPI)-anchored proteins. This suggests that the secreted epididymal proteins are transferred to spermatozoa by an unusual mechanism. Within the epididymal lumen, spermatozoa interact with small membranous vesicles named epididymosomes. Many proteins are associated with epididymosomes and the protein composition of these vesicles varies along the excurrent duct and differs from soluble intraluminal proteins. Some epididymosome-associated proteins have been identified and their functions in sperm maturation hypothesized. These include P25b, a zona pellucida binding protein, macrophage migration inhibitory factor, enzymes of the polyol pathway, HE5/CD52, type 5 glutathione peroxidase, and SPAM1 or PH-20. The electrophoretic patterns of proteins associated to epididymosomes are complex and some of these proteins are transferred to defined surface domains of epididymal spermatozoa. Epididymosomes collected from different epididymal segments interact differently with spermatozoa. This protein transfer from epididymosomes to spermatozoa is time-dependent, temperature-dependent and pH-dependent, and is more efficient in the presence of zinc. Some proteins are segregated to lipid raft domains of epididymosomes and are selectively transferred to raft domains of the sperm plasma membrane. Some evidence is presented showing that epididymosomes are secreted in an apocrine manner by the epididymal epithelial cells. In conclusion, epididymosomes are small membranous vesicles secreted in an apocrine manner in the intraluminal compartment of the epididymis and play a major role in the acquisition of new proteins by the maturing spermatozoa.
Animals
;
Antigens, Surface
;
physiology
;
Epididymis
;
physiology
;
Epithelial Cells
;
physiology
;
Humans
;
Male
;
Mice
;
Proteins
;
metabolism
;
Sperm Motility
;
physiology
;
Spermatozoa
;
physiology
2.Efficacy and safety of abrilumab, an α4β7 integrin inhibitor, in Japanese patients with moderate-to-severe ulcerative colitis: a phase II study
Toshifumi HIBI ; Satoshi MOTOYA ; Toshifumi ASHIDA ; Souken SAI ; Yukinori SAMESHIMA ; Shiro NAKAMURA ; Atsuo MAEMOTO ; Masahiro NII ; Barbara A SULLIVAN ; Robert A GASSER JR ; Yasuo SUZUKI
Intestinal Research 2019;17(3):375-386
BACKGROUND/AIMS: Inhibition of α4β7 integrin has been shown to be effective for induction and maintenance therapy in patients with ulcerative colitis (UC). We investigated the effects of varying doses of the α4β7 inhibitor abrilumab in Japanese patients with moderate-to-severe UC despite conventional treatments. METHODS: In this randomized, double-blind, placebo-controlled study, 45 UC patients were randomized to abrilumab 21 mg (n=11), 70 mg (n=12), 210 mg (n=9), or placebo (n=13) via subcutaneous (SC) injection for 12 weeks. The double-blind period was followed by a 36-week open-label period, in which all patients received abrilumab 210 mg SC every 12 weeks, and a 28-week safety follow-up period. The primary efficacy variable was clinical remission at week 8 (total Mayo score ≤2 points with no individual subscore >1 point). RESULTS: Clinical remission at week 8 was 4 out of 31 (12.9%) overall in the abrilumab groups versus 0 out of 13 in the placebo group (abrilumab 21 mg, 1/10 [10.0%]; 70 mg, 2/12 [16.7%]; 210 mg, 1/9 [11.1%]). In both the double-blind and open-label periods, fewer patients in the abrilumab groups experienced ≥1 adverse event compared with those in the placebo group. There were no cases of progressive multifocal leukoencephalopathy and no deaths. CONCLUSIONS: Abrilumab 70 mg and 210 mg yielded numerically better results in terms of clinical remission rate at Week 8 than placebo, with the 210 mg dose showing more consistent treatment effects. Abrilumab was well tolerated in Japanese patients with UC.
Asian Continental Ancestry Group
;
Colitis, Ulcerative
;
Follow-Up Studies
;
Humans
;
Japan
;
Leukoencephalopathy, Progressive Multifocal
;
Ulcer
3.Direct Puncture of the Superficial Temporal Artery in Embolization of a Scalp Arteriovenous Fistula: A Case Report
Gregory B. WALKER ; Alick P. WANG ; Jeremiah HADWEN ; Undrakh-Erdene ERDENEBOLD ; Razmik BEBEDJIAN ; Patrick SULLIVAN ; Marlise P. SANTOS ; Chad CHENIER ; Stephen KARWASKI ; Katie CARON ; Gabriella VARGA ; Jennifer LYON ; Howard J. LESIUK ; Navraj HERAN ; Manraj HERAN ; Aiman QUATEEN ; Brian J. DRAKE ; Eduardo Portela De OLIVEIRA ; Mario KONTOLEMOS ; Robert FAHED
Neurointervention 2023;18(1):67-71
We describe a minimally invasive endovascular approach to treat an arteriovenous fistula of the scalp. We performed a direct puncture of the lesion through the patient’s scalp for liquid embolic agent injection along with external compression of the superficial temporal artery to perform a “manual pressure-cooker technique.” The combination of these minimally invasive techniques resulted in an excellent clinical and radiographic outcome.